Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+mature T-cell lymphomas (MTCL)
Journal article published in 2014 by
Owen A. O'Connor,
Barbara Pro,
Tim Illidge 
,
Lorenz H. Trumper,
Emily K. Larsen,
Dana A. Kennedy
,
Lorenz H. Trumper,
Emily K. Larsen,
Dana A. Kennedy
